Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)
This study is looking at how best to give two common treatments, Radium-223 and Docetaxel, for prostate cancer that has spread to the bones. It compares different ways of giving these treatments to see which works best for improving quality of life and managing pain.
For: metastatic castration resistant prostate cancer (mCRPC) · symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)Italy - AuthorisedTherapeutic exploratory (Phase II)
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
This study is looking at a new way to treat prostate cancer that has spread. It compares two different drug combinations to see which is better at stopping the cancer from growing for at least four months.
For: prostate cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)
This study looks at a new combination of a drug called bemarituzumab with standard chemotherapy for stomach and food pipe cancer. It checks how well this new treatment shrinks tumours before surgery in people with a specific type of cancer.
For: gastric and gastro-oesophageal junction adenocarcinomasFrance